C Angel Cooper

C Angel Cooper has a strong background in project and portfolio management, with experience in various leadership roles. They currently serve as the VP, Head of Project & Portfolio Management at Silence Therapeutics plc since April 2023. Prior to that, they worked at Mallinckrodt Pharmaceuticals, where they held the positions of Vice President, Global Portfolio & Program Management & Head of Global Medical Affairs from March 2021 to March 2023, and VP, Global Portfolio & Program Management from April 2018 to March 2021. Additionally, at Mallinckrodt Pharmaceuticals, they served as the Dir of Business Operations & Chief of Staff to Chief Scientific Officer from June 2015 to April 2018. Before joining Mallinckrodt Pharmaceuticals, they worked at Pfizer as the Director of Business Operations, Medicines Development Grp, Global Innovative Pharma Business from September 2001 to May 2015. Their early career includes experience as a Study Manager for Anti-Infectives at Aventis Pharmaceuticals from August 1999 to August 2001.

C Angel Cooper's education history includes a Bachelor of Arts (BA) degree in Biology, General from La Salle University and a Master of Science (MS) degree in Microbiology, General from Thomas Jefferson University. The specific start and end years for each degree are not provided.